menu
    • menu
    [{"orgOrder":0,"company":"Bloom Science","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"BL-001","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bloom Science \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Bloom Science \/ ALS Association"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"BL-001","moa":"GABA","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloom Science","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Bloom Science \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Bloom Science \/ Leaps by Bayer"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BL-001","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bloom Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Not Applicable"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BL-001","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bloom Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Not Applicable"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"BL-001","moa":"GABA","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bloom Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Bloom Science

    Menu

    Bloom Science

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BL-001

    Therapeutic Area : Nutrition and Weight Loss

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Bloom Science's BL-001 Shows Significant Weight Loss in Phase 1 Trial

    Details : BL-001 is an investigational oral therapy designed to replicate the positive effects of the ketogenic diet, being investigated in adults ranging from healthy weight to overweight.

    Product Name : BL-001

    Product Type : Probiotic

    Upfront Cash : Inapplicable

    March 04, 2025

    Lead Product(s) : BL-001

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BL-001

    Therapeutic Area : Neurology

    Study Phase : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Cl...

    Details : BL-001 is a first-in-class, orally delivered, live biotherapeutic product being developed by Bloom Science for the treatment of multiple neurological diseases, including Dravet syndrome and ALS.

    Product Name : BL-001

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    August 17, 2023

    Lead Product(s) : BL-001

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BL-001

    Therapeutic Area : Neurology

    Study Phase : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dr...

    Details : BL-001 is a live biotherapeutic product, designed to modulate GABA and other key bioenergetic pathways to suppress hyperexcitability which is a key driver in seizures associated with dravet syndrome and other rare developmental and epileptic encephalopat...

    Product Name : BL-001

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    April 25, 2023

    Lead Product(s) : BL-001

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BL-001

    Therapeutic Area : Neurology

    Study Phase : Preclinical

    Sponsor : Leaps by Bayer

    Deal Size : $12.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Bloom Science Raises USD $12 Million in Series A Financing

    Details : The investment will enable Bloom to file an Investigational New Drug (IND) application for BL-001 in refractory epilepsy and advance into Phase I clinical trials, as well as further expand development of its platform and advance its research and talent a...

    Product Name : BL-001

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    December 09, 2021

    Lead Product(s) : BL-001

    Therapeutic Area : Neurology

    Highest Development Status : Preclinical

    Sponsor : Leaps by Bayer

    Deal Size : $12.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed

    Bloom Science

    U.S.A arrow
    ASPEN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BL-001

    Therapeutic Area : Neurology

    Study Phase : Preclinical

    Sponsor : ALS Association

    Deal Size : $0.5 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    The ALS Association Awards Bloom Science for Novel Microbiota-based Therapies

    Details : Bloom is leveraging its GOLD platform in combination with strong pre-clinical data to advance a new generation of therapeutics aimed at managing gut microbiota.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    March 17, 2020

    Lead Product(s) : BL-001

    Therapeutic Area : Neurology

    Highest Development Status : Preclinical

    Sponsor : ALS Association

    Deal Size : $0.5 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth